Nama's AI scorecard currently rates CRISPR Therapeutics Sell (3.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does CRSP report earnings?

CRISPR Therapeutics's next scheduled report is on Nov 9, 2026. Analysts expect EPS of -$1.06.

What is the CRSP price target?

The median analyst price target from 19 analysts is $80.00, with a range of $44.00 – $291.00.

Is CRSP Shariah compliant?

Nama's AAOIFI-style screen reads CRISPR Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

CRISPR Therapeutics (CRSP)

Healthcare · Biotechnology · NASDAQ

CRISPR Therapeutics (CRSP) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $4.86B and a free-cash-flow yield of -8.2%. Over the most recent reported fiscal year, revenue declined 100.0%. Nama's AI scorecard rates it Sell, 3.0 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Sell · 3.0/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Lagging · -7.5% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-47.3%

How far the last close sits under the highest price of the past five years.

Market cap	$4.86B
Trailing P/E	—
Price / book	2.8
Price / sales	357.6
FCF yield	-8.2%
Dividend yield	—
Gross margin	-1691.3%
Operating margin	-4857.6%
Net margin	-4101.3%
Revenue growth (YoY)	-100.0%
Revenue growth (3-yr annual)	-100.0%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	1.8
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

CRSP earnings

Next report: Nov 9, 2026 (Q3 2026, EPS estimate -$1.06). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2026	Aug 3, 2026	-$0.94	-$1.18	+20.3%	$10.00M
Q1 2026	May 4, 2026	-$1.28	-$1.23	-4.1%	$1.00M
Q4 2025	Feb 12, 2026	-$1.37	-$1.23	-11.4%	$0
Q3 2025	Nov 10, 2025	-$1.17	-$1.29	+9.3%	$0

CRSP analyst price target

Median target $80.00 from 19 analysts, ranging $44.00 – $291.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live CRSP data on Nama Insights →

Recent Congressional trades

CRISPR Therapeutics trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
James M Inhofe	Senate	Sell	$15,001 - $50,000	—
James M Inhofe	Senate	Buy	$15,001 - $50,000	—

CRSP FAQ

Is CRSP a buy?: Nama's AI scorecard currently rates CRISPR Therapeutics Sell (3.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does CRSP report earnings?: CRISPR Therapeutics's next scheduled report is on Nov 9, 2026. Analysts expect EPS of -$1.06.
What is the CRSP price target?: The median analyst price target from 19 analysts is $80.00, with a range of $44.00 – $291.00.
Is CRSP Shariah compliant?: Nama's AAOIFI-style screen reads CRISPR Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.